Tumor progression and metastasis: Role of translational deregulation

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3077-3084

  Nasr, Zeina ^a   Pelletier, Jerry ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Cancer; eIF4E; eIF4F; Metastasis; Review; Translation control

Indexed keywords

INITIATION FACTOR 4A; INITIATION FACTOR 4E; INITIATION FACTOR 4F; INITIATION FACTOR 4G; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN;

CANCER GROWTH; CARCINOGENESIS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE CONTROL; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSLATION DEREGULATION; TRANSLATION INITIATION; TRANSLATION REGULATION;

EID: 84865681715     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Weber GF, Ashkar S, Glimcher MJ and Cantor H: Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271: 509-512, 1996.
2. Weber GF, Bronson RT, Ilagan J, Cantor H, Schmits R and Mak TW: Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res 62: 2281-2286, 2002.
3. Rapp UR, Korn C, Ceteci F, Karreman C, Luetkenhaus K, Serafin V, Zanucco E, Castro I and Potapenko T: Myc is a metastasis gene for non-small-cell lung cancer. PLoS One 4: e6029, 2009.
4. Grandori C, Cowley SM, James LP and Eisenman RN: The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16: 653-699, 2000.
5. Nicolson GL: Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 47: 1473-1487, 1987.
6. Liteplo RG, Frost P and Kerbel RS: Genetic and epigenetic aspects of tumor progression and tumor heterogeneity. Basic Life Sci 33: 285-305, 1985.
7. Sager R: Expression genetics in cancer: shifting the focus from DNA to RNA. Proc Natl Acad Sci USA 94: 952-955, 1997.
8. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R and Sonenberg N: Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 13: 1422-1437, 1999.
9. Hou J, Lam F, Proud C and Wang S: Targeting mnks for cancer therapy. Oncotarget 3: 118-131, 2012.
10. Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004.
11. Gingras AC, Raught B and Sonenberg N: mTOR signaling to translation. Curr Top Microbiol Immunol 279: 169-197, 2004.
12. Duncan R, Milburn SC and Hershey JW: Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. J Biol Chem 262: 380-388, 1987.
13. Malina A, Cencic R and Pelletier J: Targeting translation dependence in cancer. Oncotarget 2: 76-88, 2011.
14. De Benedetti A and Graff JR: eIF-4E expression and its role in malignancies and metastases. Oncogene 23: 3189-3199, 2004.
15. Heys SD, Park KG, McNurlan MA, Calder AG, Buchan V, Blessing K, Eremin O and Garlick PJ: Measurement of tumour protein synthesis in vivo in human colorectal and breast cancer and its variability in separate biopsies from the same tumour. Clin Sci 80: 587-593, 1991.
16. Lazaris-Karatzas A, Montine KS and Sonenberg N: Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345: 544-547, 1990.
17. Tan A, Bitterman P, Sonenberg N, Peterson M and Polunovsky V: Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1. Oncogene 19: 1437-1447, 2000.
18. Polunovsky VA, Rosenwald IB, Tan AT, White J, Chiang L, Sonenberg N and Bitterman PB: Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol 16: 6573-6581, 1996.
19. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J and Lowe SW: Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337, 2004.
20. Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, Sonenberg N and Colburn NH: The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 23: 26-37, 2003.
21. Cencic R, Hall DR, Robert F, Du Y, Min J, Li L, Qui M, Lewis I, Kurtkaya S, Dingledine R, Fu H, Kozakov D, Vajda S and Pelletier J: Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci USA 108: 1046-1051, 2011.
22. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, Wang T, Sams L, Geeganage S, Douglass LE, Neubauer BL, Dean NM, Blanchard K, Shou J, Stancato LF, Carter JH and Marcusson EG: Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 117: 2638-2648, 2007.
23. Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG, Brem B, Greger H, Lowe SW, Porco JA, Jr. and Pelletier J: Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 118: 2651-2660, 2008.
24. Cencic R, Carrier M, Galicia-Vazquez G, Bordeleau ME, Sukarieh R, Bourdeau A, Brem B, Teodoro JG, Greger H, Tremblay ML, Porco JA Jr. and Pelletier J: Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS ONE 4: e5223, 2009.
25. Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, Halperin JA and Wagner G: Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128: 257-267, 2007.
26. Lazaris-Karatzas A, Smith MR, Frederickson RM, Jaramillo ML, Liu YL, Kung HF and Sonenberg N: Ras mediates translation initiation factor 4E-induced malignant transformation. Genes Dev 6: 1631-1642, 1992.
27. Fukuchi-Shimogori T, Ishii I, Kashiwagi K, Mashiba H, Ekimoto H and Igarashi K: Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res 57: 5041-5044, 1997.
28. Zhang L, Pan X and Hershey JW: Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells. J Biol Chem 282: 5790-5800, 2007.
29. Jiang H, Coleman J, Miskimins R and Miskimins WK: Expression of constitutively active 4EBP-1 enhances p27Kip1 expression and inhibits proliferation of MCF7 breast cancer cells. Cancer Cell Int 3: 2, 2003.
30. Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB and Polunovsky VA: Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5: 553-563, 2004.
31. Pons B, Peg V, Vazquez-Sanchez MA, Lopez-Vicente L, Argelaguet E, Coch L, Martinez A, Hernandez-Losa J, Armengol G and Ramon YCS: The effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer model. Int J Oncol 39: 1337-1345, 2011.
32. Ko SY, Guo H, Barengo N and Naora H: Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E. Clin Cancer Res 15: 4336-4347, 2009.
33. Graff JR, Boghaert ER, De Benedetti A, Tudor DL, Zimmer CC, Chan SK and Zimmer SG: Reduction of translation initiation factor 4E decreases the malignancy of ras-transformed cloned rat embryo fibroblasts. Int J Cancer 60: 255-263, 1995.
34. Nathan CO, Carter P, Liu L, Li BD, Abreo F, Tudor A, Zimmer SG and De Benedetti A: Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene 15: 1087-1094, 1997.
35. DeFatta RJ, Nathan CO and De Benedetti A: Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope 110: 928-933, 2000.
36. Graff JR, De Benedetti A, Olson JW, Tamez P, Casero RA Jr. and Zimmer SG: Translation of ODC mRNA and polyamine transport are suppressed in ras-transformed CREF cells by depleting translation initiation factor 4E. Biochem Biophys Res Commun 240: 15-20, 1997.
37. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D and Gleave ME: A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97: 1287-1296, 2005.
38. El-Hashemite N, Walker V, Zhang H and Kwiatkowski DJ: Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 63: 5173-5177, 2003.
39. Huber S, Bruns CJ, Schmid G, Hermann PC, Conrad C, Niess H, Huss R, Graeb C, Jauch KW, Heeschen C and Guba M: Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 71: 771-777, 2007.
40. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW and Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128-135., 2002.
41. Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M and Ishikura H: Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 98: 726-733, 2007.
42. Meric-Bernstam F: Translation initiation factor 4E (eIF4E): prognostic marker and potential therapeutic target. Ann Surg Oncol 15: 2996-2997, 2008.
43. Wang R, Geng J, Wang JH, Chu XY, Geng HC and Chen LB: Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma. Lung Cancer 66: 237-244, 2009.
44. Flowers A, Chu QD, Panu L, Meschonat C, Caldito G, Lowery-Nordberg M and Li BD: Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome. Surgery 146: 220-226, 2009.
45. Holm N, Byrnes K, Johnson L, Abreo F, Sehon K, Alley J, Meschonat C, Md QC and Li BD: A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer. Ann Surg Oncol 15: 3207-3215, 2008.
46. McClusky DR, Chu Q, Yu H, Debenedetti A, Johnson LW, Meschonat C, Turnage R, McDonald JC, Abreo F and Li BD: A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann Surg 242: 584-590; discussion 590-582, 2005.
47. Lahat G, Dhuka AR, Hallevi H, Xiao L, Zou C, Smith KD, Phung TL, Pollock RE, Benjamin R, Hunt KK, Lazar AJ and Lev D: Angiosarcoma: clinical and molecular insights. Ann Surg 251: 1098-1106, 2010.
48. Fan S, Ramalingam SS, Kauh J, Xu Z, Khuri FR and Sun SY: Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther 8: 1463-1469, 2009.
49. Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, Baselga J and Ramon y Cajal S: 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 67: 7551-7555, 2007.
50. Coleman LJ, Peter MB, Teall TJ, Brannan RA, Hanby AM, Honarpisheh H, Shaaban AM, Smith L, Speirs V, Verghese ET, McElwaine JN and Hughes TA: Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer 100: 1393-1399, 2009.
51. Rojo F, Najera L, Lirola J, Jimenez J, Guzman M, Sabadell MD, Baselga J and Ramon y Cajal S: 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 13: 81-89, 2007.
52. Yeh CJ, Chuang WY, Chao YK, Liu YH, Chang YS, Kuo SY, Tseng CK, Chang HK and Hsueh C: High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma. Virchows Arch 458: 171-178, 2011.
53. Zimmer SG and Graff JR: The Emerging Role for the mRNA Cap-Binding Protein, EIF-4E, in Metastatic Progression. In: Cancer Metastasis-Related Genes. Welch DR (ed.). Netherlands, Kluwer Academic Publishers, pp. 247-65, 2002.
54. Zimmer SG, DeBenedetti A and Graff JR: Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 20: 1343-1351, 2000.
55. Fowler CL, Zimmer CC and Zimmer SG: Spontaneous progression of a stage IV-S human neuroblastoma cell line involves the increased expression of the protooncogenes ras and eukaryotic initiation factor 4E. Pediatr Pathol Mol Med 19: 433-447, 2000.
56. Byrnes K, White S, Chu Q, Meschonat C, Yu H, Johnson LW, Debenedetti A, Abreo F, Turnage RH, McDonald JC and Li BD: High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann Surg 243: 684-690; discussion 691-682, 2006.
57. Zhou S, Wang GP, Liu C and Zhou M: Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer. BMC Cancer 6: 231, 2006.
58. DeFatta RJ, Li Y and De Benedetti A: Selective killing of cancer cells based on translational control of a suicide gene. Cancer Gene Ther 9: 573-578, 2002.
59. DeFatta RJ, Chervenak RP and De Benedetti A: A cancer gene therapy approach through translational control of a suicide gene. Cancer Gene Ther 9: 505-512, 2002.
60. Kevil C, Carter P, Hu B and DeBenedetti A: Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation. Oncogene 11: 2339-2348, 1995.
61. Siegele B, Cefalu C, Holm N, Sun G, Tubbs J, Meschonat C, Odaka Y, DeBenedetti A, Ghali GE, Chu Q, Mathis JM and Li BD: eIF4E-targeted suicide gene therapy in a minimal residual mouse model for metastatic soft-tissue head and neck squamous cell carcinoma improves disease-free survival. J Surg Res 148: 83-89, 2008.
62. Martinez-Montemayor MM, Otero-Franqui E, Martinez J, De La Mota-Peynado A, Cubano LA and Dharmawardhane S: Individual and combined soy isoflavones exert differential effects on metastatic cancer progression. Clin Exp Metastasis 27: 465-480, 2010.
63. Goldson TM, Vielhauer G, Staub E, Miller S, Shim H and Hagedorn CH: Eukaryotic initiation factor 4E variants alter the morphology, proliferation, and colony-formation properties of MDA-MB-435 cancer cells. Mol Carcinog 46: 71-84, 2007.
64. Shankar J, Messenberg A, Chan J, Underhill TM, Foster LJ and Nabi IR: Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Cancer Res 70: 3780-3790, 2010.
65. Provenzani A, Fronza R, Loreni F, Pascale A, Amadio M and Quattrone A: Global alterations in mRNA polysomal recruitment in a cell model of colorectal cancer progression to metastasis. Carcinogenesis 27: 1323-1333, 2006.
66. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J and Lowe SW: Dissecting eIF4E action in tumorigenesis. Genes Dev 21: 3232-3237, 2007.
67. Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, Dowless MS, Iversen PW, Parsons S, Ellis KE, McCann DJ, Pelletier J, Furic L, Yingling JM, Stancato LF, Sonenberg N and Graff JR: Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res 71: 1849-1857, 2011.
68. Nasr Z, Robert F, Porco JA Jr., Muller WJ and Pelletier J: eIF4F suppression in breast cancer affects maintenance and progression. Oncogene, 2012.
69. Smith AP, Verrecchia A, Faga G, Doni M, Perna D, Martinato F, Guccione E and Amati B: A positive role for Myc in TGFβ-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene 28: 422-430, 2009.
70. Martinez C, Churchman M, Freeman T and Ilyas M: Osteopontin provides early proliferative drive and may be dependent upon aberrant c-myc signalling in murine intestinal tumours. Exp Mol Pathol 88: 272-277, 2010.
71. Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov JP, Liu XS, Shioda T, Toner M, Loda M, Brown M, Brugge JS and Ramaswamy S: MYC regulation of a "poor- prognosis" metastatic cancer cell state. Proc Natl Acad Sci USA 107: 3698-3703, 2010.
72. Chan CH, Lee SW, Li CF, Wang J, Yang WL, Wu CY, Wu J, Nakayama KI, Kang HY, Huang HY, Hung MC, Pandolfi PP and Lin HK: Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat Cell Biol 12: 457-467, 2010.
73. Lin CJ, Cencic R, Mills JR, Robert F and Pelletier J: c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res 68: 5326-5334, 2008.
74. Lin CJ, Nasr Z, Premsrirut PK, Porco JA, Jr., Hippo Y, Lowe SW and Pelletier J: Targeting Synthetic Lethal Interactions between Myc and the eIF4F Complex Impedes Tumorigenesis. Cell Rep 1: 325-333, 2012.